secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xeris Biopharma Holdings, Inc. (XERS)
CIK:        0001867096
Form:       8-K
Filed at:   2026-08-06T11:12:47+00:00
Accession:  0001867096-26-000063
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xeris Q2 revenue $92.1M (+29% YoY); Recorlev up 81%; tightens FY guidance to $385-390M
--------------------------------------------------------------------------------

- Net product revenue $91.0M (+34% YoY); Recorlev $56.8M (+81%), Gvoke $22.5M (-4%), Keveyis $11.7M (+2%).
- Net loss $31.1M includes ~$31M non-cash charge from 2028 Convertible Notes exchange; adjusted EBITDA $19.3M (+$6.7M YoY).
- Gross margin improved to 86% (Q2 2025: 82%) on favorable product mix.
- Full-year 2026 total revenue guidance tightened to $385-390M from prior range.
- USPTO Notice of Allowance for new Keveyis patent expected to extend IP protection through at least 2039.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1867096/000186709626000063/0001867096-26-000063-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1867096/000186709626000063/xers-20260806.htm
  HTML page:      https://secwatch.observer/filing/0001867096-26-000063

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer